Regeneron and Sanofi announce positive results from four pivotal alirocumab trials
Regeneron and Sanofi announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting PCSK9. All four ongoing trials met their primary efficacy endpoint. August 31, 2014